Based on promising in vitro activity alone and in combination [122,143,144,145], vorinostat, a pan-HDAC inhibitor approved for the treatment of cutaneous T-cell lymphoma, was also studied in MM patients. This evidence concerns the gene HDAC9 and Miyoshi myopathy.